1. Name and Address of Reporting Person
   Ahlberg Gregory A
   
   (Last) (First) (Middle)
   100 ABBOTT PARK ROAD
   
   (Street) ABBOTT PARK
   (City) IL 60064

2. Date of Event Requiring Statement (Month/Day/Year)
   10/01/2020

3. Issuer Name and Ticker or Trading Symbol
   ABBOTT LABORATORIES [ ABT ]

4. Relationship of Reporting Person(s) to Issuer
   Director
   10% Owner X
   Other (specify below)
   Senior Vice President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing
   Form filed by One Reporting Person
   X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Amount of Securities Beneficially Owned</th>
<th>Ownership Form: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common shares without par value</td>
<td>6,526</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common shares without par value</td>
<td>10,596(1)</td>
<td>I</td>
<td>Profit Sharing Trust</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Ownership Form: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Option (right to buy)²</td>
<td>08/14/2018</td>
<td>08/13/2027</td>
<td>Common shares</td>
<td>6,000</td>
<td>48.98</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Option (right to buy)³</td>
<td>02/16/2019</td>
<td>02/15/2028</td>
<td>Common shares</td>
<td>46,403</td>
<td>59.94</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Option (right to buy)⁴</td>
<td>02/22/2020</td>
<td>02/21/2029</td>
<td>Commons shares</td>
<td>38,190</td>
<td>75.9</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Option (right to buy)⁵</td>
<td>02/21/2021</td>
<td>02/20/2030</td>
<td>Common shares</td>
<td>32,244</td>
<td>87.72</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Explanations of Responses:
2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,334 on August 14, 2018, 5,333 on August 14, 2019 and 5,333 on August 14, 2020.
3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,468 on February 16, 2019, 15,467 on February 16, 2020 and 15,468 on February 16, 2021.
5. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,748 on each of February 21, 2021, February 21, 2022 and February 21, 2023.

Jessica H. Paik, by power of attorney for Gregory A. Ahlberg, 10/05/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(vi).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: September 16, 2020

/s/ Gregory A. Ahlberg
Signature of Reporting Person

Gregory A. Ahlberg

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064